Evidence map›Paper›PMID 40707623›Full record

ArticleScientific reports2025

A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade.

Işıl Altıntaş, Kristina B Nürmberger, Andrea Imle, Anna-Lena Krause, Marike M van Beuge, Aras Toker, Andreea Ioan-Facsinay, Jordan Blum, Alexander Muik, Frank J Beurskens and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Işıl AltıntaşGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Kristina B NürmbergerBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Andrea ImleBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Anna-Lena KrauseBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Marike M van BeugeGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Aras TokerBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Andreea Ioan-FacsinayGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Jordan BlumGenmab US, Inc, 777 Scudders Mill Road, Bldg. 2, Plainsboro, NJ, 08536, USA.
Alexander MuikBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Frank J BeurskensGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Rob N de JongGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
David P E SatijnGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Friederike GiesekeBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Bart-Jan de KreukGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Maarten van der KroefGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands.
Sina Fellermeier-KopfBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Tahamtan AhmadiGenmab US, Inc, 777 Scudders Mill Road, Bldg. 2, Plainsboro, NJ, 08536, USA.
Özlem TüreciBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany.
Esther C W BreijGenmab B.V, Uppsalalaan 15, 3584 CT, Utrecht, The Netherlands. ebreij@gmail.com.
Uğur ŞahinBioNTech SE, An der Goldgrube 12, 55131, Mainz, Germany. ugur.sahin@biontech.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HexaBody-CD27 (GEN1053/BNT313) is an investigational novel agonistic CD27 antibody engineered to enhance T-cell costimulation and promote antitumor immunity. Through the introduction of a hexamerization-enhancing mutation in the IgG Fc domain, HexaBody-CD27 was designed to drive clustering and activation of CD27 via intermolecular Fc:Fc interactions between membrane-bound antibodies, independent of crosslinking by FcγR-bearing cells. HexaBody-CD27 carries an Fc-silencing mutation to prevent T-cell depletion through Fc-mediated effector functions. In vitro, HexaBody-CD27 induced CD27 receptor signaling independent of FcγR-mediated crosslinking in a reporter assay. It also enhanced T-cell proliferation, cytotoxic activity and proinflammatory cytokine secretion in primary human lymphocytes. In contrast to benchmark IgG1 CD27 antibodies, HexaBody-CD27 did not induce phagocytosis of T cells in vitro. HexaBody-CD27 promoted ex vivo tumor infiltrating lymphocyte (TIL) expansion in non-small cell lung cancer (NSCLC) specimens, in particular of CD8

Indexed as

Immunoglobulin Fc FragmentsProgrammed Cell Death 1 ReceptorT-LymphocytesTumor Necrosis Factor Receptor Superfamily, Member 7Cell Line, TumorCell ProliferationHumansImmunoglobulin GLung NeoplasmsLymphocyte ActivationLymphocytes, Tumor-InfiltratingReceptors, IgGImmunoglobulin Fc FragmentsImmunoglobulin GPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, IgGTumor Necrosis Factor Receptor Superfamily, Member 7Combination therapyCostimulatory moleculesImmunotherapyMonoclonal antibodyT cell

Identifiers

PMID40707623
PMCPMC12289993

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.